John Canan - Net Worth and Insider Trading

John Canan Net Worth

The estimated net worth of John Canan is at least $2 Million dollars as of 2024-05-15. John Canan is the Sr.V-P Finc-Global Controller of Merck & Co Inc and owns about 14,043 shares of Merck & Co Inc (MRK) stock worth over $2 Million. John Canan is also the Director of REV Group Inc and owns about 6,363 shares of REV Group Inc (REVG) stock worth over $160,602. Details can be seen in John Canan's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that John Canan has not made any transactions after 2018-06-25 and currently still holds the listed stock(s).

Transaction Summary of John Canan

To

John Canan Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, John Canan owns 4 companies in total, including Acasti Pharma Inc (ACST) , REV Group Inc (REVG) , and Merck & Co Inc (MRK) among others .

Click here to see the complete history of John Canan’s form 4 insider trades.

Insider Ownership Summary of John Canan

Ticker Comapny Transaction Date Type of Owner
ACST Acasti Pharma Inc 2020-04-01 director
REVG REV Group Inc 2018-06-25 director
MRK Merck & Co Inc 2014-02-11 Senior V-P & Controller
2009-11-03 Senior V-P & Controller

John Canan Latest Holdings Summary

John Canan currently owns a total of 2 stocks. Among these stocks, John Canan owns 14,043 shares of Merck & Co Inc (MRK) as of February 11, 2014, with a value of $2 Million and a weighting of 91.84%. John Canan also owns 6,363 shares of REV Group Inc (REVG) as of June 25, 2018, with a value of $160,602 and a weighting of 8.16%.

Latest Holdings of John Canan

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
MRK Merck & Co Inc 2014-02-11 14,043 128.66 1,806,772
REVG REV Group Inc 2018-06-25 6,363 25.24 160,602

Holding Weightings of John Canan


John Canan Form 4 Trading Tracker

According to the SEC Form 4 filings, John Canan has made a total of 0 transactions in Merck & Co Inc (MRK) over the past 5 years. The most-recent trade in Merck & Co Inc is the sale of 10,000 shares on February 11, 2014, which brought John Canan around $557,000.

According to the SEC Form 4 filings, John Canan has made a total of 0 transactions in REV Group Inc (REVG) over the past 5 years. The most-recent trade in REV Group Inc is the acquisition of 5,040 shares on June 25, 2018, which cost John Canan around $80,842.

Insider Trading History of John Canan

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

John Canan Trading Performance

GuruFocus tracks the stock performance after each of John Canan's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by John Canan is -6.43%. GuruFocus also compares John Canan's trading performance to market benchmark return within the same time period. The performance of stocks bought by John Canan within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how John Canan's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of John Canan

Average Return

Average return per transaction

Outperforming Transactions

0 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -2.94
Relative Return to S&P 500(%) -7.69

John Canan Ownership Network

Ownership Network List of John Canan

No Data

Ownership Network Relation of John Canan


John Canan Owned Company Details

What does Acasti Pharma Inc do?

Who are the key executives at Acasti Pharma Inc?

John Canan is the director of Acasti Pharma Inc. Other key executives at Acasti Pharma Inc include Chief Medical Officer R. Loch Macdonald , Chief Executive Officer Prashant Kohli , and VP Clinical Operations Carrie D'andrea .

Acasti Pharma Inc (ACST) Insider Trades Summary

Over the past 18 months, John Canan made no insider transaction in Acasti Pharma Inc (ACST). Other recent insider transactions involving Acasti Pharma Inc (ACST) include a net purchase of 676,371 shares made by Vimal Kavuru , and a net purchase of 381 shares made by Donald Olds .

In summary, during the past 3 months, insiders sold 0 shares of Acasti Pharma Inc (ACST) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Acasti Pharma Inc (ACST) were sold and 676,752 shares were bought by its insiders, resulting in a net purchase of 676,752 shares.

Acasti Pharma Inc (ACST)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Acasti Pharma Inc Insider Transactions

No Available Data

John Canan Mailing Address

Above is the net worth, insider trading, and ownership report for John Canan. You might contact John Canan via mailing address: C/o Rev Group, Inc., 111 East Kilbourn Avenue, Suite 2600, Milwaukee Wi 53202.

Discussions on John Canan

No discussions yet.